Herbalife HLF
- Market cap
- $1.4B
- PE
- 8.6×
- 10y median 10.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- 6.2×
- Revenue, 12 months
- $5.3B
- +6% on a year ago
- Net margin
- 3.2%
- Free cash flow yield
- 23.1%
Herbalife trades at 8.6× trailing earnings, near its ten-year median. Revenue was $5.3B over the last twelve months, up 6% on a year earlier with a 3% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B+3% | $1.3B+1% | $1.3B−3% | $1.2B−3% | $1.2B−1% | $1.2B−3% | $1.3B−2% | $1.3B+3% | $1.3B+6% | $1.3B+8% | $1.3B+5% | $1.4B+6% | |
| Cost of revenue | $287.6M+8% | $285M−5% | $283.1M−6% | $268.7M−11% | $267.5M−7% | $265.2M−7% | $276.9M−2% | $284.2M+6% | $288.3M+8% | $291.1M+10% | $296.3M+7% | $306.1M+8% |
| Gross profit | $927.4M+1% | $979.3M+3% | $998M−1% | $971.6M−1% | $939.9M+1% | $956.5M−2% | $982.2M−2% | $989.5M+2% | $994.7M+6% | $1B+7% | $1B+5% | $1B+6% |
| SG&A | $474.3M+9% | $492.2M+3% | $502.3M+9% | $444M−3% | $436.9M−8% | $833.7M+69% | $854.4M+70% | $863.7M+95% | $2.1B+385% | $893.2M+7% | $902.2M+6% | $905.6M+5% |
| $55.8M−37% | $71.9M+2% | $80.4M−35% | $127.1M+19% | $106.5M+91% | $122.8M+71% | $132.6M+65% | $125.8M−1% | $99.8M−6% | $138.4M+13% | $128.3M−3% | $138.5M+10% | |
| Interest expense | $49.6M+14% | $37.9M−4% | $57.7M+50% | $56.5M+47% | $66.2M+34% | $52M+37% | $53.6M−7% | $51M−10% | $57.8M−13% | $46.8M−10% | $37.4M−30% | $31.9M−38% |
| Pre-tax income | $17.7M−73% | $34M+9% | $12.2M−86% | $70.6M+2% | $52.6M+197% | $70.8M+108% | $79M+548% | $74.8M+6% | $50.5M−4% | $91.6M+29% | −$3.7M | $106.6M+43% |
| $7.5M−25% | $9.7M+439% | $7.5M−70% | $23.2M−12% | −$125.3M | $20.4M+110% | $29.8M+297% | $31.7M+37% | −$34.6M−72% | $30.4M+49% | $22.8M−24% | $49.5M+56% | |
| Net income | $10.2M−81% | $24.3M−17% | $4.7M−92% | $47.4M+11% | $177.9M+1644% | $50.4M+107% | $49.3M+949% | $43.2M−9% | $85.4M−52% | $61.9M+23% | −$26.3M | $58.8M+36% |
| $0.10−82% | $0.24−17% | $0.05−92% | $0.46+7% | $1.74+1640% | $0.49+104% | $0.48+860% | $0.42−9% | $0.81−53% | $0.57+16% | −$0.25 | $0.55+31% | |
| 100.8M+2% | 100.7M+1% | 101.7M+2% | 101.9M+2% | 102.2M+1% | 102.2M+2% | 103.3M+2% | 104M+2% | 104.8M+3% | 108.4M+6% | 104.5M+1% | 107.3M+3% |
EPS, diluted: 10 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Herbalife's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HLFHerbalife | $1.4B | 8.6× | 10.3× | 0.3× | +6% | 3.2% | |
| CNMDCONMED | $1.4B | 19.3× | 52.9× | 1.0× | +2% | 5.4% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PNTGPennant | $1.4B | 45.0× | 46.5× | 1.3× | +38% | 2.9% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| TRUPTrupanion | $1.3B | 58.0× | 58.8× | 0.9× | +12% | 1.5% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| ALHCAlignment Healthcare | $1.5B | 53.8× | 76.9× | 0.3× | +36% | 0.6% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| USPHU S Physical Therapy | $1.3B | 96.5× | 42.1× | 1.6× | +11% | 4.0% | |
| Peer median | $1.4B | 42.0× | 52.8× | 1.1× | +12% | 2.7% |
Investors who own it
Investors we follow who held Herbalife at the end of Jun 30, 2026, from their 13F filings.
- Seth KlarmanBaupost Group2.2% of portfolio
More on Herbalife
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 196Healthcare stocks with the highest free cash flow yield
- #8of 170Healthcare stocks with the lowest PE ratio
- #5of 10Medical distribution stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .